<DOC>
	<DOCNO>NCT00004908</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage cancer cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness radiation therapy cyclophosphamide plus peripheral stem cell transplantation treat patient recurrent refractory Hodgkin 's disease non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Radiation Therapy Cyclophosphamide Plus Peripheral Stem Cell Transplantation Treating Patients With Recurrent Refractory Hodgkin 's Disease Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity autologous peripheral blood stem cell transplantation follow involved field radiotherapy , high dose cyclophosphamide , total body irradiation patient recurrent refractory Hodgkin 's disease non-Hodgkin 's lymphoma . II . Determine response patient treat regimen . OUTLINE : Patients undergo involved field radiotherapy day -16 -7 . Patients receive cyclophosphamide IV 2 hour day -6 -5 . Patients undergo total body irradiation twice daily day -4 -1 . Autologous peripheral blood stem cell reinfused day 0 . Patients follow every month 1 year . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove Hodgkin 's disease nonHodgkin 's lymphoma refractory standard therapy relapse follow initial response Eligible nonHodgkin 's lymphoma : Low grade Intermediate grade Immunoblastic large cell lymphoma ( high grade ) Eligible involved field radiotherapy , cyclophosphamide , total body irradiation No CNS nonHodgkin 's lymphoma Hodgkin 's disease A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : Physiologic age 65 Performance status : ECOG 02 Life expectancy : At least 2 month Hematopoietic : Not specify Hepatic : Not specify Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 50 mL/min creatinine 1.52 mg/dL Cardiovascular : No active heart disease ( congestive heart failure , history myocardial infarction within past 3 month , significant arrhythmia ) require medication Pulmonary : No nonneoplastic pulmonary disease ( e.g. , chronic obstructive pulmonary disease ) would preclude intensive chemotherapy DLCO least 50 % predicted* FEV1 and/or FVC least 75 % predicted* * Unless due underlie lymphoma Hodgkin 's disease Other : No concurrent medical condition would preclude aggressive cytotoxic chemotherapy HIV negative No clinical evidence AIDS PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>